378 related articles for article (PubMed ID: 28736643)
41. Comparative effectiveness and resource utilization of
Braiteh F; Patel MB; Parisi M; Ni Q; Park S; Faria C
Cancer Manag Res; 2017; 9():141-148. PubMed ID: 28461766
[TBL] [Abstract][Full Text] [Related]
42. Association between progression-free survival and metal stent patency in patients with advanced pancreatic cancer.
Ahn J; Ahn DW; Park J; Jung K; Lee JC; Hwang JH; Jeong JB; Kim J
J Gastrointest Oncol; 2022 Aug; 13(4):1981-1988. PubMed ID: 36092328
[TBL] [Abstract][Full Text] [Related]
43. Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel: A retrospective study.
Tozuka Y; Ueno M; Kobayashi S; Morimoto M; Fukushima T; Sano Y; Kawano K; Hanaoka A; Tezuka S; Asama H; Moriya S; Morinaga S; Ohkawa S; Maeda S
Oncol Lett; 2022 Oct; 24(4):375. PubMed ID: 36238838
[TBL] [Abstract][Full Text] [Related]
44. Advancements in the management of pancreatic cancer: 2013.
Saif MW
JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
[TBL] [Abstract][Full Text] [Related]
45. Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma.
Bukhari N; Abdalla K; Ibnshamsa F; Alselwi W; Al-Shakir S; Alqahtani M
Cureus; 2021 Oct; 13(10):e18756. PubMed ID: 34796055
[TBL] [Abstract][Full Text] [Related]
46. The prognostic impact of tumour location and first-line chemotherapy regimen in locally advanced pancreatic cancer.
Takeda T; Sasaki T; Mie T; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Jpn J Clin Oncol; 2021 Apr; 51(5):728-736. PubMed ID: 33611490
[TBL] [Abstract][Full Text] [Related]
47. FOLFIRINOX
Cho IR; Kang H; Jo JH; Lee HS; Chung MJ; Park JY; Park SW; Song SY; An C; Park MS; Bang S
World J Gastrointest Oncol; 2020 Feb; 12(2):182-194. PubMed ID: 32104549
[TBL] [Abstract][Full Text] [Related]
48. FOLFIRINOX as First-line Chemotherapy in Japanese Patients Suffering from Metastatic Pancreatic Cancer (KOBE FOLFIRINOX Study).
Hatachi Y; Mohan SR; Kotake T; Satake H; Okita Y; Yasui H; Tsuji A
Cancer Diagn Progn; 2022; 2(1):101-106. PubMed ID: 35400007
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: A multicenter retrospective analysis.
Yoshida Y; Kobayashi S; Ueno M; Morizane C; Tsuji K; Maruki Y; Mori K; Watanabe K; Ohba A; Furuta M; Todaka A; Tsujimoto A; Ozaka M; Okano N; Yane K; Umemoto K; Kawamoto Y; Terashima T; Tsumura H; Doi K; Shioji K; Asagi A; Kojima Y; Suzuki E; Toshiyama R; Furukawa M; Naganuma A; Suzuki R; Miwa H; Ikeda M; Furuse J
Pancreatology; 2022 Dec; 22(8):1159-1166. PubMed ID: 36150984
[TBL] [Abstract][Full Text] [Related]
50. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
51. FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules.
Foschini F; Napolitano F; Servetto A; Marciano R; Mozzillo E; Carratù AC; Santaniello A; De Placido P; Cascetta P; Butturini G; Frigerio I; Regi P; Silvestris N; Delcuratolo S; Vasile E; Vivaldi C; Bianco C; De Placido S; Formisano L; Bianco R
Ther Adv Med Oncol; 2020; 12():1758835920947970. PubMed ID: 33062062
[TBL] [Abstract][Full Text] [Related]
52. Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country.
Zahir MN; Jabbar AA
Asian Pac J Cancer Prev; 2015; 16(14):6001-6. PubMed ID: 26320487
[TBL] [Abstract][Full Text] [Related]
53. Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions.
Lambert A; Gavoille C; Conroy T
Therap Adv Gastroenterol; 2017 Aug; 10(8):631-645. PubMed ID: 28835777
[TBL] [Abstract][Full Text] [Related]
54. A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer.
Ozaka M; Ishii H; Sato T; Ueno M; Ikeda M; Uesugi K; Sata N; Miyashita K; Mizuno N; Tsuji K; Okusaka T; Furuse J
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1017-1023. PubMed ID: 29633005
[TBL] [Abstract][Full Text] [Related]
55. Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study.
Komori A; Otsu S; Shimokawa M; Otsuka T; Koga F; Ueda Y; Nakazawa J; Arima S; Fukahori M; Okabe Y; Makiyama A; Taguchi H; Honda T; Shibuki T; Nio K; Ide Y; Ureshino N; Mizuta T; Shirakawa T; Mitsugi K
Int J Clin Oncol; 2023 Aug; 28(8):1073-1081. PubMed ID: 37209158
[TBL] [Abstract][Full Text] [Related]
56. Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma.
Hegewisch-Becker S; Aldaoud A; Wolf T; Krammer-Steiner B; Linde H; Scheiner-Sparna R; Hamm D; Jänicke M; Marschner N;
Int J Cancer; 2019 Mar; 144(5):981-990. PubMed ID: 30006989
[TBL] [Abstract][Full Text] [Related]
57. Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer.
Han SY; Kim DU; Seol YM; Kim S; Lee NK; Hong SB; Seo HI
World J Clin Cases; 2020 Sep; 8(17):3718-3729. PubMed ID: 32953848
[TBL] [Abstract][Full Text] [Related]
58. A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.
Ahn DH; Krishna K; Blazer M; Reardon J; Wei L; Wu C; Ciombor KK; Noonan AM; Mikhail S; Bekaii-Saab T
Ther Adv Med Oncol; 2017 Feb; 9(2):75-82. PubMed ID: 28203300
[TBL] [Abstract][Full Text] [Related]
59. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
Mahaseth H; Brutcher E; Kauh J; Hawk N; Kim S; Chen Z; Kooby DA; Maithel SK; Landry J; El-Rayes BF
Pancreas; 2013 Nov; 42(8):1311-5. PubMed ID: 24152956
[TBL] [Abstract][Full Text] [Related]
60. Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response.
Nguyen KT; Kalyan A; Beasley HS; Singhi AD; Sun W; Zeh HJ; Normolle D; Bahary N
J Gastrointest Oncol; 2017 Jun; 8(3):556-565. PubMed ID: 28736642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]